重症军团菌肺炎单药与联合治疗:多中心回顾性观察研究
该多中心回顾性观察研究纳入2017年1月1日至2022年12月31日法国五家大学医院及Elbeuf综合医院ICU收治的93例成人军团菌肺炎患者,比较单药组(13例,92.3%用氟喹诺酮)与联合治疗组(80例,除1例外均为氟喹诺酮联合大环内酯)的结局。主要终点28天死亡率两组无显著差异(15.4% vs 12.5%),90天死亡率、有创通气时长、ICU住院时长及抗生素相关不良事件亦无显著差异。作者认为单药尤其氟喹诺酮可能作为重症军团菌肺炎联合治疗的替代选择,但需前瞻性随机研究确认。
要点
- 93例ICU重症军团菌肺炎患者中,单药组28天死亡率为15.4%,联合治疗组为12.5%,两组无显著差异。
- 单药组13例中12例(92.3%)使用氟喹诺酮,1例(7.7%)使用大环内酯。
- 联合治疗组80例中,除1例用氟喹诺酮联合利福平外,其余均为氟喹诺酮联合大环内酯。
- 90天死亡率单药组23.1% vs 联合治疗组16.25%,无显著差异;有创通气时长16.5天 vs 10天,ICU住院时长12天 vs 11.5天。
- 抗生素相关不良事件为皮疹(7例,87.5%)和意识模糊(1例,12.5%),两组无显著差异(0% vs 10%)。
适用人群与场景
- 2017年1月1日至2022年12月31日入住Rouen、Caen、Amiens、Lille大学医院及Elbeuf综合医院ICU的成人军团菌肺炎患者。
- 单药组13例,联合治疗组80例(其中30%为非全程联合,即从单药转为联合;70%为全程联合)。
处置流程与药物剂量
- 法国2012年指南推荐重症病例使用氟喹诺酮单药或氟喹诺酮联合大环内酯,未偏向某一策略。
- 本研究中单药组12例(92.3%)接受氟喹诺酮,1例(7.7%)接受大环内酯。
- 联合治疗组除1例使用氟喹诺酮联合利福平外,其余均为氟喹诺酮联合大环内酯。
研究设计与关键结果
- 多中心回顾性观察队列研究,纳入93例ICU成人军团菌肺炎患者,比较单药与联合治疗,主要终点为ICU入院后28天死亡率。
- 28天死亡率单药组15.4% vs 联合治疗组12.5%,无显著差异。
- 90天死亡率单药组23.1% vs 联合治疗组16.25%,无显著差异。
- 有创通气时长单药组16.5天 vs 联合治疗组10天,ICU住院时长单药组12天 vs 联合治疗组11.5天,均无显著差异。
- 抗生素相关不良事件单药组0% vs 联合治疗组10%,无显著差异;不良事件为皮疹7例(87.5%)和意识模糊1例(12.5%)。
- 需高流量氧疗59例(69.4%),有创通气65例(69.9%),急性呼吸窘迫综合征64例(68.8%)。
证据类型、等级与局限
- 证据类型:多中心回顾性观察队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,单药尤其氟喹诺酮可能作为ICU重症军团菌肺炎联合治疗的替代选择。
- 作者指出需前瞻性随机研究确认结果并完善治疗推荐。
指南或共识出处
- 法国2012年指南推荐重症军团菌肺炎使用氟喹诺酮单药或氟喹诺酮联合大环内酯,未偏向某一策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The incidence of Legionella pneumophila pneumonia is rising. Since 2012, French guidelines recommend fluoroquinolone monotherapy or combination therapy with a fluoroquinolone and macrolide for severe cases, without favoring a strategy. This study assessed the impact of antibiotic strategies on mortality in severe Legionella pneumophila pneumonia in ICU patients. MATERIALS AND METHODS: We conducted a retrospective, observational multicenter cohort study across ICUs at the university hospitals of Rouen, Caen, Amiens, Lille, and Elbeuf General Hospital, covering the period from January 1, 2017, to December 31, 2022. All adult patients admitted to ICUs for Legionella pneumophila were included. Patients were divided into two groups: monotherapy and combination therapy. The combination therapy group included those who received exclusive combination therapy and those who transitioned from monotherapy to combination therapy (non-exclusive combination therapy). The primary endpoint was 28-day mortality after ICU admission. Secondary outcomes included 90-day mortality, ventilation duration, ICU stay length, and antibiotic-related adverse events. RESULTS: We included 93 patients: 13 in the monotherapy group and 80 in the combination therapy group, with 24 (30%) receiving non-exclusive and 56 (70%) exclusive combination therapy. In the monotherapy group, 12 patients (92.3%) received fluoroquinolones and 1 (7.7%) received a macrolide. Combination therapy consisted of fluoroquinolones and macrolides in all but one case, treated with fluoroquinolones and rifampicin. High-flow oxygen was required in 59 patients (69.4%), invasive ventilation in 65 patients (69.9%), and acute respiratory distress syndrome occurred in 64 patients (68.8%). The 28-day mortality was not significantly different between the two groups (15.4% vs. 12.5). No significant differences were observed in invasive ventilation duration (16.5 vs. 10 days), ICU stay length (12 vs. 11.5 days), or 90-day mortality (23.1% vs. 16.25%). Adverse events attributed to antibiotherapy were cutaneous rash (n = 7; 87.5%) and confusion (n = 1 ;12.5%) and were not significantly different between the two groups (0% vs. 10%). CONCLUSION: Our study suggests that monotherapy, particularly with fluoroquinolones, may be an alternative to combination therapy in managing severe Legionella pneumophila pneumonia in the ICU. Prospective and randomized studies would be necessary to confirm these results and refine treatment recommendations.
参考来源
- Bouteiller M, Cossé C, Beduneau G, et al. Monotherapy versus combination therapy in severe Legionella pneumonia: a multicenter retrospective observational study. Crit Care. 2026. PMID: 41764574. doi:10.1186/s13054-026-05907-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。